Dec 27, 2016, RASP OTC Disclosure & News Service – Rasna Therapeutics, Inc. (OTCQB:RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced that it has closed a private placement to accredited investors of an aggregate 3,366,667 shares of common stock at $0.60 per share for gross proceeds of $2.02 million. The Company intends to use the proceeds for clinical development and working capital. About Rasna Therapeutics, Inc. Rasna Therapeutics, Inc. is a development stageRead more
- American Rebel (OTCQB: AREB) Sales Grow 79% on Amazon
- GeoVax Comments on Recent Vaccine Development Study Funded by the Gates Foundation
SMALL CAP MARKET NEWS
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More